Revolution Medicines (FRA:42Z) Float Percentage Of Total Shares Outstanding: 94.65% (As of Jul. 11, 2026)


FRA:42Z Revolution Medicines Inc FRA:42Z
30 GF Score
Price €167.00
GF Value €0.41
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Revolution Medicines Float Percentage Of Total Shares Outstanding?

Revolution Medicines FRA:42Z -0.92% 30 Float Percentage Of Total Shares Outstanding is 94.65% as of Jul. 11, 2026. GuruFocus rates FRA:42Z with a GF Score™ of 30/100 and a GF Value™ of €0.41 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Revolution Medicines's float shares is 201.23 Mil. Revolution Medicines's total shares outstanding is 212.60 Mil. Revolution Medicines's float percentage of total shares outstanding is 94.65%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Revolution Medicines's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Revolution Medicines's Institutional Ownership is 42.88%.

FRA:42Z
30GF Score
Revolution Medicines Inc FRA:42Z
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Revolution Medicines Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Revolution Medicines's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=201.23/212.60
=94.65%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 94.65% mean?
Revolution Medicines (FRA:42Z) has a Float Percentage Of Total Shares Outstanding of 94.65% as of Jul. 11, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Revolution Medicines and its competitors.
Is Revolution Medicines' Float Percentage Of Total Shares Outstanding too high?
Revolution Medicines' current Float Percentage Of Total Shares Outstanding is 94.65%. Overall, Revolution Medicines has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Revolution Medicines' Float Percentage Of Total Shares Outstanding compare to ALNY and ONC?
Revolution Medicines' Float Percentage Of Total Shares Outstanding of 94.65% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Revolution Medicines and its competitors. Revolution Medicines's current Float Percentage Of Total Shares Outstanding is 94.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revolution Medicines stock overvalued right now?
Based on GuruFocus' analysis, Revolution Medicines (FRA:42Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.41, compared to a current price of €167.00 — trading 40631.7% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 94.65%. Revolution Medicines' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Revolution Medicines (FRA:42Z), the current Float Percentage Of Total Shares Outstanding is 94.65% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Revolution Medicines (FRA:42Z) Overvalued in 2026?

Based on GuruFocus' analysis, Revolution Medicines stock appears to be overvalued. The current stock price of €167.00 is trading 40631.7% above its estimated GF Value™ of €0.41. GuruFocus considers Revolution Medicines to be Significantly Overvalued.

Key valuation signals for FRA:42Z:

  • Float Percentage Of Total Shares Outstanding: 94.65%
  • GF Value™: €0.41 vs. price of €167.00 (40631.7% above fair value)
  • GF Score™: 30/100 with 4 warning signs

No single metric tells the full story. See the FRA:42Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Revolution Medicines Business Description

Address 700 Saginaw Drive, Redwood City, CA, USA, 94063
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
30GF Score

Get the complete analysis for FRA:42Z

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€167.00
Price
€0.41
GF Value